We are live on ! Find out more
FGP

Foyston, Gordon, & Payne Portfolio holdings

AUM $468M
1-Year Est. Return 6.67%
This Fund
S&P 500
This Quarter Est. Return
+5.05%
1 Year Est. Return
+6.67%
3 Year Est. Return
+57.25%
5 Year Est. Return
+83.16%
10 Year Est. Return
+253.32%
AUM
$787M
AUM Growth
-$24.3M
Cap. Flow
-$58.4M
Cap. Flow %
-7.41%
Top 10 Hldgs %
35.43%
Holding
86
New
1
Increased
12
Reduced
49
Closed
5

Top Sells

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$13.5M
2
R icon
Ryder
R
+$5.64M
3
IBN icon
ICICI Bank
IBN
+$4.68M
4
JBL icon
Jabil
JBL
+$4.55M
5
BHI
Baker Hughes
BHI
+$4.14M

Sector Composition

Rank Sector Weight
1 Healthcare 23.58%
2 Technology 15.83%
3 Financials 15.07%
4 Energy 11.76%
5 Consumer Staples 9.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TEVA icon
1
Teva Pharmaceuticals
TEVA
$42.5B
$35.4M 4.49%
674,888
+313,877
+87% +$16M
CAG icon
2
Conagra Brands
CAG
$7.72B
$33.5M 4.26%
1,451,267
-96,706
-6% -$2.34M
PNC icon
3
PNC Financial Services
PNC
$96.6B
$30.7M 3.9%
344,989
-23,089
-6% -$1.97M
APA icon
4
APA Corp
APA
$14.9B
$28.2M 3.59%
280,633
-22,425
-7% -$2.03M
MET icon
5
MetLife
MET
$61.3B
$26.8M 3.41%
541,362
+10,920
+2% +$511K
MDT icon
6
Medtronic
MDT
$117B
$26.3M 3.34%
412,222
+102,313
+33% +$6.22M
BG icon
7
Bunge Global
BG
$22.2B
$24.9M 3.17%
329,615
-10,240
-3% -$792K
FCX icon
8
Freeport-McMoran
FCX
$110B
$24.7M 3.14%
677,728
-85,050
-11% -$2.91M
BAX icon
9
Baxter International
BAX
$13.5B
$24.4M 3.1%
621,234
+105,093
+20% +$4.2M
COV
10
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
$23.9M 3.04%
265,207
-28,515
-10% -$2.13M
MSFT icon
11
Microsoft
MSFT
$3.81T
$23.5M 2.99%
564,657
-29,312
-5% -$1.19M
CHKP icon
12
Check Point Software Technologies
CHKP
$14.1B
$21.7M 2.75%
323,205
-15,785
-5% -$1.04M
WBA
13
DELISTED
Walgreens Boots Alliance
WBA
$18.6M 2.37%
251,502
-18,130
-7% -$1.27M
BHI
14
DELISTED
Baker Hughes
BHI
$17.7M 2.25%
237,772
-59,526
-20% -$4.14M
JNJ icon
15
Johnson & Johnson
JNJ
$646B
$17.1M 2.18%
163,824
-730
-0.4% -$73.8K
AVT icon
16
Avnet
AVT
$7.27B
$17M 2.16%
384,216
-3,132
-0.8% -$138K
R icon
17
Ryder
R
$9.43B
$16.1M 2.05%
182,905
-67,356
-27% -$5.64M
STT icon
18
State Street
STT
$53.1B
$15.5M 1.96%
229,877
-8,998
-4% -$592K
MOS icon
19
The Mosaic Company
MOS
$7.5B
$15M 1.91%
303,714
-42,808
-12% -$2.11M
JBL icon
20
Jabil
JBL
$31.6B
$14.9M 1.89%
711,076
-244,544
-26% -$4.55M
DBD
21
DELISTED
Diebold Nixdorf Incorporated
DBD
$14.7M 1.87%
365,650
-38,390
-10% -$1.47M
TDW icon
22
Tidewater
TDW
$4.61B
$14.5M 1.85%
8,032
-374
-4% -$620K
SEM
23
DELISTED
Select Medical
SEM
$14M 1.78%
1,669,105
-323,129
-16% -$2.51M
TUP
24
DELISTED
Tupperware Brands Corporation
TUP
$13.6M 1.73%
162,899
-10,735
-6% -$902K
RGA icon
25
Reinsurance Group of America
RGA
$16B
$13M 1.66%
165,339
-3,772
-2% -$294K

Similar funds

Foyston, Gordon, & Payne's Q2 2014 Portfolio in Review

As of Q2 2014, Foyston, Gordon, & Payne held 86 positions worth $787M, down 3% from $812M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Foyston, Gordon, & Payne withdrew a net $58.4M in Q2 2014, closing 5 positions and reducing 49 holdings. Its most notable exit was iShares Russell 2000 ETF, an estimated $13.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, up from 20% a quarter earlier, followed by Technology and Financials.

Against the trend, Foyston, Gordon, & Payne opened a new position in Compañía de Cervecerías Unidas worth $693K.

  • Foyston, Gordon, & Payne's largest Q2 2014 buy was Compañía de Cervecerías Unidas: 29,600 shares worth $693K.
  • Foyston, Gordon, & Payne added most to Teva Pharmaceuticals in Q2 2014, an estimated $16M increase.
  • Foyston, Gordon, & Payne's biggest Q2 2014 reduction was Ryder, cutting an estimated $5.64M.
  • Foyston, Gordon, & Payne fully exited iShares Russell 2000 ETF in Q2 2014, selling an estimated $13.5M.
  • Foyston, Gordon, & Payne's ten largest holdings make up 35% of its $787M portfolio in Q2 2014.
  • Foyston, Gordon, & Payne opened 1 new position and closed 5 in Q2 2014.
  • Foyston, Gordon, & Payne's portfolio value fell 3% quarter-over-quarter to $787M.

Based on Foyston, Gordon, & Payne's 13F filing for Q2 2014, filed 14 Aug 2014.